$SNTI News

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K

Senti Biosciences Announces Completion Of Type B Initial Comprehensive Multidisciplinary RMAT Meeting With FDA Regarding SENTI-202, Logic Gated Off-The-Shelf CAR-NK Cell Therapy For R/R AML And Updated Phase 1 Clinical Data

Senti Biosciences Enters Up To $40M Convertible Note Financing Agreement With Celadon Affiliate

Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026; Upon Effectiveness Of Holding Company Reorganization, Senti Biosciences Holdings Would Become Successor Issuer To Co

Senti Biosciences Publishes New Peer-Reviewed Research In Cell Systems Demonstrating Its Systematic Framework For Engineering NOT-Gated Chimeric Antigen Receptor Circuits In Both T Cells And Natural Killer Cells

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11

Senti Biosciences Q4 EPS $(0.53) Misses $(0.48) Estimate, Sales $22.000K Miss $666.667K Estimate

Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Evaluating SENTI-202, CD33/FLT3-Targeting Logic Gated CAR NK Cell Therapy, In Patients With R/R AML

Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

Senti Biosciences Announces New Employment Inducement Grants

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?

SNTI stock has given up its prior gain. Senti Biosciences shares were trading higher after the company announced new data from its ongoing multinational, multicenter clinical trial of SENTI-202

SNTI stock has given up its prior gain. Senti Biosciences shares were trading higher after the company announced new data from its ongoing multinational, multicenter clinical trial of SENTI-202

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

Senti Biosciences shares are trading higher after the company announced new data from its ongoing multinational, multicenter clinical trial of SENTI-202

Senti Biosciences Says FDA Grants Regenerative Medicine Advanced Therapy Designation To SENTI-202 For Treatment Of R/R Hematologic Malignancies, Including AML

Senti Bio Receives FDA RMAT Designation For SENTI-202 In Relapsed Or Refractory AML After Orphan Drug Status, Backed By 50% ORR And 42% CR/CRh At RP2D